0001144204-17-048089.txt : 20170914 0001144204-17-048089.hdr.sgml : 20170914 20170914190037 ACCESSION NUMBER: 0001144204-17-048089 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170912 FILED AS OF DATE: 20170914 DATE AS OF CHANGE: 20170914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'Toole David D CENTRAL INDEX KEY: 0001491140 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38193 FILM NUMBER: 171086573 MAIL ADDRESS: STREET 1: 1640 MARENGO STREET CITY: LOS ANGELES STATE: CA ZIP: 90033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OPIANT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001385508 STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0731 BUSINESS ADDRESS: STREET 1: 201 SANTA MONICA BOULEVARD STREET 2: SUITE 500 CITY: SANTA MONICA STATE: CA ZIP: 90401 BUSINESS PHONE: (310) 598-5410 MAIL ADDRESS: STREET 1: 201 SANTA MONICA BOULEVARD STREET 2: SUITE 500 CITY: SANTA MONICA STATE: CA ZIP: 90401 FORMER COMPANY: FORMER CONFORMED NAME: Lightlake Therapeutics Inc. DATE OF NAME CHANGE: 20091009 FORMER COMPANY: FORMER CONFORMED NAME: Madrona Ventures, Inc. DATE OF NAME CHANGE: 20070108 4 1 v475189_4.xml OWNERSHIP DOCUMENT X0306 4 2017-09-12 0 0001385508 OPIANT PHARMACEUTICALS, INC. OPNT 0001491140 O'Toole David D C/O OPIANT PHARMACEUTICALS, INC. 201 SANTA MONICA BOULEVARD, SUITE 500 SANTA MONICA CA 90401 0 1 0 0 Chief Financial Officer Stock Option (right to buy) 36.00 2017-09-12 4 A 0 150000 0 A 2018-09-12 2027-09-11 Common Stock 150000 150000 D On September 12, 2017, the reporting person was granted an option to purchase 150,000 shares of common stock. The option vests as follows: Twenty-five percent (25%) of the shares of common stock underlying the option shall vest on the one-year anniversary of the date of grant, and 2.083% of the shares of common stock underlying the option shall vest monthly thereafter, becoming fully vested on the four-year anniversary of the date of grant. /s/ David D. O'Toole 2017-09-14